← SynDRA
NATEGLINIDE
SynDRA canonical compound SYN0001830 — structure-anchored drug synonym record
| Clinical phase | Launched |
|---|
| Approval status | Approved · Rx/OTC |
|---|
| Primary target(s) | ABCC8 |
|---|
| Mechanism of action | Insulin secretagogue |
|---|
| Indication | diabetes mellitus |
|---|
| Disease area | endocrinology |
|---|
All known targets
- ABCC8
- KCNJ11
- ABCC9
- CYP3A4
- INS
- KCNJ10
- PPARG
- Slc22a6
Mechanisms of action (all sources)
- Insulin secretagogue
- KCNJ11 BLOCKER
- Sulfonylurea receptor 1, Kir6.2 blocker
- ABCC8 BLOCKER
Bioactivity evidence (ChEMBL activities table — not curator-asserted)
- ABCB1
- FYN
- MMP9
- MMP1
- MC5R
- MC4R
- MC3R
- MAPK3
- MAPK14
- MAPK1
- MAOA
- LMNA
- LCK
- KCNH2
- KAT2A
- HTR6
- HTR2C
- HTR2B
- HTR2A
- HRH2
- HRH1
- HMGCR
- HDAC6
- NPY1R
- NPY2R
- NR3C1
- SLC6A2
- VDR
- TDP1
- TBXAS1
- TACR2
- TACR1
- SLCO1B3
- SLCO1B1
- SLC6A4
- SLC6A3
- SIGMAR1
- OPRD1
- PTPRC
- PTGS2
Screening evidence (raw PubChem HTS — uncurated, known false-positive rate)
Drug classes
- Glinide
- Potassium Channel Antagonists
- Hypoglycemic Agents
ATC classes
- A10B · BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS
Cross-references
Synonyms
- STARLIX
- D-Nateglinide
- glinate
- glunate
- natelide
- senaglinide
- Nateglinida
- D-nateglinide
- Senaglinide
- A-4166
- AY-4166
- AY4166
- DJN-608
- NSC-758695
- SDZ-DJN-608
- Starlix
- Starsis
- Trazec
- Fastic
- IPCCPA
- Nateglinide [INN]
- Novartis brand of nateglinide
- Nate-glinide
- Starlix (TN)
- YM-026
- N-((4-isopropylcyclohexyl)carbonyl)phenylalanine
- Nateglinide, (D-Phe)-isomer
- Nateglinide, (cis,D-Phe)-isomer
- N-{[4-(propan-2-yl)cyclohexyl]carbonyl}phenylalanine
- N-{[trans-4-(propan-2-yl)cyclohexyl]carbonyl}-D-phenylalanine
- AY 4166
- SDZ-DJN 608
- A 4166
- nateglinida
- nateglinidum
- NSC 758695
- A4166
Reported adverse events
- Arthropathy
- Bronchitis
- Cough
- Dizziness
- Hypersensitivity
- Jaundice
- Rash
Look up NATEGLINIDE in the interactive SynDRA portal →